3197 results about "Excipient" patented technology

The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides Tmax value of less than 30 minutes upon said administration. Other aspects and embodiments are contemplated and described.The invention also provides a pharmaceutical composition for intranasal administration comprising a triptan, a pharmaceutically acceptable vehicle and a mucosal permeation enhancer, wherein upon said administration said composition provides a Tmax substantially equivalent to subcutaneous administration of said triptan. Other aspects and embodiments are contemplated and described.

The invention relates to the technical field of medicine quality detection, and particularly discloses an optical detection method and system for the content of vitamin tablets. The method comprises the following steps: driving an optical fiber probe array to carry out three-dimensional multi-angle near-infrared scanning through a multi-axis mechanical arm, and collecting reflection spectrum data; a weighted spectrum is generated through derivative spectrum analysis and double evaluation, and auxiliary material noise is corrected and separated in combination with subspace projection and a dynamic kernel function; performing spectral vector projection and regression coefficient iterative optimization through an online PLS model, and synthesizing an error coefficient based on a four-level index retrieval standard library to perform dual-channel feedback; and finally, fusing the credibility weight to output a detection result of the binding confidence. The method realizes nondestructive and high-precision detection of the vitamin tablets, has the beneficial effects of multi-dimensional data fusion, dynamic error compensation and high model adaptability, and remarkably improves the detection accuracy and reliability.

The invention discloses a pharmaceutical composition containing melogabalin besylate with good stability and a preparation method of the pharmaceutical composition. The pharmaceutical composition comprises an active component melogabalin besylate, one or more excipients, an adsorbent, a lubricant, a coating agent and an antioxidant, the antioxidant is a combination of L-ascorbyl palmitate and tartaric acid. The invention also provides a preparation method of the melogabalin besylate tablet, and the stability of the melogabalin besylate tablet prepared by the method is obviously improved.

The invention provides a composition capable of penetrating an intestinal barrier by oral administration. The composition contains a carrier or an auxiliary material of a targeted Microflod cell Dectin-1 receptor, and one or / and a plurality of medicinal components / components, wherein the carrier or the auxiliary material of the target Microflood cell Dectin-1 receptor is beta-glucan, and the carrier or the auxiliary material of the target Microflood cell Dectin-1 receptor is beta-glucan. The effective components / components are traditional Chinese medicine effective components / components, or / and probiotics, or / and chemical medicine components, or / and biological medicines. The invention relates to a composition capable of realizing oral administration and penetrating through an intestinal barrier, which is based on the discovery of the inventor that the composition reaches colon through gastrointestinal tracts, targets colon Microflood cells, is taken by the Microflood cells, penetrates through the intestinal barrier and enters immune tissue Colonic Patches of a colon submucosa. Based on the research, the composition disclosed by the invention can be used for treating various diseases, such as ulcerative colitis, Crohn's disease, colon cancer, rheumatoid arthritis or bacterial pneumonia after being orally taken and absorbed by rectum.

The present invention provides a dry powder formulation of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or excipients. The formulations described herein may be used to treat a disease or condition, such as depression or alcohol use disorder in a subject in need thereof.

The present disclosure provides storage stable solid compositions including a biopharmaceutical agent and a polyacrylamide-based copolymer. The inventors have demonstrated that particular polyacrylamide-based copolymers can be used as stabilizing excipients in lyophilized formulations of biopharmaceutical agents. Also provided are methods of reconstituting and using the compositions, including methods of administering the reconstituted composition to a human subject in need thereof via injection, e.g., subcutaneous injection.

The present invention provides a dry powder formulation of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or excipients. The formulations described herein may be used to treat a disease or condition, such as depression or alcohol use disorder in a subject in need thereof.

The invention relates to a sodium channel regulator for inhibiting Nav1.8, and provides a compound as shown in a formula I which can be used as the sodium channel regulator for inhibiting Nav1.8, and an isomer of the compound, or a pharmaceutically acceptable salt of the compound, the invention also provides a pharmaceutical composition containing the compound and the isomer thereof, or the pharmaceutically acceptable salt thereof and a carrier or excipient, and a pharmaceutical application of the pharmaceutical composition as a NaV1.8 inhibitor (such as pain, respiratory diseases, neurological disorders, mental diseases and the like).

The invention relates to a ligand-effector moiety provided with at least one saponin and antibody-effector moiety provided with at least one saponin. An aspect of the invention is a composition comprising the ligand-effector moiety provided with at least one saponin or the antibody-effector moiety provided with at least one saponin of the invention. The invention also relates to an antibody-drug conjugate comprising covalently linked saponin and to an antibody-oligonucleotide conjugate comprising covalently linked saponin. An aspect of the invention relates to a pharmaceutical composition comprising the ligand-effector moiety provided with at least one saponin or the antibody-effector moiety provided with at least one saponin of the invention, and optionally further comprising a pharmaceutically acceptable excipient. The invention also relates to the ligand-effector moiety provided with at least one saponin or the antibody-effector moiety provided with at least one saponin, for use as a medicament. The invention also relates to the ligand-effector moiety provided with at least one saponin or the antibody-effector moiety provided with at least one saponin of the invention for use in the treatment or prophylaxis of a cancer.

The invention discloses a preparation method of perindopril amlodipine tablets, and belongs to the field of pharmacy. The perindopril amlodipine tablet is prepared from the following raw material medicines: arginine perindopril and amlodipine besylate and auxiliary materials: lactose, microcrystalline cellulose, hydrophobic colloidal silicon dioxide and magnesium stearate. The preparation method of the perindopril amlodipine tablet comprises the following steps: weighing according to the prescription amount, crushing and sieving the raw materials for pretreatment, sieving the whole particles of the auxiliary materials for pretreatment, premixing, feeding and total mixing, tabletting and the like. The prepared perindopril amlodipine tablet is relatively good in quality, high in stability and relatively few in waste products.

The present invention relates to a crop nutrition and fortifying composition comprising: i. Elemental sulfur; ii. One or more water insoluble or water soluble magnesium salts or derivatives or mixtures thereof; iii. One or more water-insoluble or water-soluble potash fertilizers or salts or derivatives or mixtures thereof; iv. One or more water insoluble or water soluble iron salts or derivatives or mixtures thereof; v. One or more water insoluble or water soluble zinc salts or derivatives or mixtures thereof; vi. One or more water-insoluble or water-soluble boron salts or derivatives or mixtures thereof; vii. At least one trace element selected from the group consisting of water-insoluble or water-soluble vanadium salts or derivatives or mixtures thereof and water-insoluble or water-soluble selenium salts or derivatives or mixtures thereof; and viii. One or more excipients wherein the composition comprises microparticles having a size in the range of 0.1 to 50 microns, and wherein the total content of the water-soluble salts, derivatives or mixtures in the composition does not exceed 80% of the total weight of the composition. The invention also relates to a method for preparing the crop nutrition and fortifying composition and a method for treating a plant, a seed, a crop, plant propagation material, a locus, parts thereof or soil with the crop nutrition and fortifying composition.

A synergistic insecticidal composition comprising of (A) Isocycloseram; (B) an insecticide from chlorantraniliprole, cyantraniliprole, cyclaniliprole, tetraniliprole, tetrachlorantraniliprole, tyclopyrazoflor, cyhalodiamide, flubendiamide, fluchlordiniliprole, tiorantraniliprole; and (C) one or more insecticides selected from the given list thereof. The present invention further relates to process for preparing the said compositions in specific amount. The present invention further relates to the process for preparing the said composition along with at least one formulation excipient; and formulations thereof. The present invention further relates to the synergistic compositions, wherein active ingredient present in fixed amount shows synergy in an insecticidal activity.

The invention relates to a fluxazole amide composition and a preparation method thereof. More specifically, the present invention relates to synergistic compositions of fluoxazole amides and methods of preparing stable and non-phytotoxic formulations, the synergistic composition comprises fluoxazole amide or an agrochemically acceptable salt thereof, an insecticide selected from diamides, at least one or more compounds selected from insecticides, fungicides and plant health additives, and an agrochemically acceptable excipient. The invention further relates to pesticidal compositions for controlling harmful pests in plants, which can be formulated, are environmentally safe, exhibit high efficacy, and act on disease resistance management or delay the development of disease resistance by employing a variety of modes of action, plant tolerance against insect pests, mites, fungal and bacterial diseases and abiotic stress is increased and the overall health and vigor of the treated plant is improved.

The invention relates to the field of biotechnology and female health care, in particular to a stachyose composition for promoting micro-ecological regulation of lactobacillus and application of the stachyose composition, and the composition comprises stachyose and pharmaceutically acceptable auxiliary materials. The stachyose is used as prebiotics to selectively promote proliferation and colonization of the lactobacillus crispatus, the combination of 1%-5% of the stachyose and 0.1%-0.5% of the lactic acid can promote proliferation of the lactobacillus crispatus, the lactobacillus crispatus is one or more of the lactobacillus crispatus, the lactobacillus plantarum and the lactobacillus acidophilus, and the combination of 1%-5% of the stachyose and 0.1%-0.5% of the lactic acid can inhibit gardnerella and candida albicans. The stachyose composition disclosed by the invention is in the form of slow-release gel and bath foam; the composition can be used for treating or preventing bacterial vaginitis, colpitis mycotica and related symptoms, has the advantages of no antibiotics, no drug resistance, high safety and the like, and is suitable for the fields of vagina local nursing and micro-ecological regulation.

The invention relates to the technical field of traditional Chinese medicine component detection and discloses a rapid detection method for traditional Chinese medicine compound components. The method comprises the following steps: performing Raman spectrum scanning on a traditional Chinese medicine compound sample to generate component spectrum distribution information, and performing fitting by adopting a partial least square algorithm to determine a local component anomaly risk area; meanwhile, atomic force microscopic imaging is carried out, a microstructure distribution map is generated, and a potential component mismatch feature region is marked through texture feature extraction and pattern recognition. And generating a detection optimization adjustment region based on the space coordinates of the region, analyzing the gradient change in the molecular arrangement direction of the region to evaluate the component distribution offset state, and analyzing the interface bonding state of the active component and the auxiliary material to evaluate the component interaction coupling strength. And finally, on the basis of an evaluation result, whether the real-time parameter calibration is started in the detection optimization adjustment area is judged through a dual-channel decision-making mechanism. According to the method, correlation analysis of component spectrums and microtopographies is realized, and the accuracy and pertinence of traditional Chinese medicine compound component detection are improved.

The present invention provides a pharmaceutical composition, the composition comprises a therapeutically effective amount of bumetanib, one or more specific antioxidants and other necessary one or more pharmaceutically acceptable pharmaceutic adjuvants, and the specific antioxidants are selected from one or more of fat-soluble vitamin C derivatives or phenolic antioxidants. In addition, the invention also discloses a method for improving the stability of the bumetanib pharmaceutical composition. According to the technical scheme, the problems of generation and growth of N-nitroso bumetanib and other related substances in the production and storage process of the bumetanib solid preparation are effectively solved, and the drug stability and the medication safety are remarkably improved.

The invention belongs to the technical field of pharmaceutical analysis, and relates to a method for detecting the content of povidone K30. According to the method, the content of povidone K30 in the medicinal preparation is detected by adopting a high performance liquid chromatography; detection conditions of the high performance liquid chromatography are as follows: a chromatographic column is a C18-AQ column; a mobile phase is a phosphate solution. The method has the characteristics of high accuracy, strong specificity and the like for detecting the content of povidone K30 in the pharmaceutical preparation, can overcome the interference of other auxiliary materials in the pharmaceutical preparation, and has important application value in development and consistency evaluation of the pharmaceutical preparation.

The invention belongs to the technical field of biological medicines, and particularly relates to an umbilical cord mesenchymal stem cell preparation and application thereof in treating prostate diseases. According to the umbilical cord mesenchymal stem cell preparation, the umbilical cord mesenchymal stem cells of the third generation to the sixth generation and the neurofilament peptide serve as active components, pharmaceutically acceptable auxiliary materials are matched, the prostate index can be remarkably reduced, the concentration of PACP and SRD5A2 can be reduced, and the umbilical cord mesenchymal stem cell preparation has a remarkable curative effect on prostatic hyperplasia. And the umbilical cord mesenchymal stem cells of the third generation to the sixth generation and the neurofilament peptide supplement each other and have a synergistic effect, so that a remarkable progress is generated.

The invention relates to the technical field of oral membranes, in particular to a multilayer oral membrane and a preparation method thereof. The invention provides an oral membrane composition, which comprises semeglutide and pharmaceutically acceptable auxiliary materials, and is characterized in that the composition is formed by combining a drug-containing biological adhesion layer and a backing layer, and the backing layer mainly comprises a membrane forming material, a solvent and a plasticizer; the drug-containing biological adhesion layer mainly comprises semeglutide, a film-forming material, an adhesive, a pH regulator, a flavoring agent and a solvent. By preparing the double-layer oral membrane, the semeglutide is administrated through the oral cavity, and after the insoluble or slowly eroded / dissolved backing layer (preventing saliva from dissolving the medicine) and the adhesive layer containing the main medicine are combined together, the one-way delivery of the main medicine can be realized; through experiments, it is accidentally found that when temperature-sensitive materials such as poloxamer are added to be combined with a conventional adhesive for use, the residence time of the medicine in the oral mucosa can be remarkably prolonged, the curative effect of the medicine is improved, and the main mechanism is that after the medicine is administered, in the oral temperature environment, after the medicine makes contact with mucus on the surface of the oral mucosa, the oral mucosa does not adhere to the oral mucosa. And after the entanglement and piling effects among poloxamer micelles are intensified to form gel, the gel and a conventional adhesive are cooperated to improve the adhesion between the oral membrane and the oral mucosa. Besides, the medicine can be removed at any time, blood sugar can be better controlled, T2DM complications can be better reduced, a more ideal taking mode is provided for weight loss patients, and a new administration mode is provided for reducing blood sugar and reducing weight. The prepared oral cavity membrane is small in size, light in weight, thin, convenient to apply, carry and transport, safe and environmentally friendly to use and capable of meeting the requirements of old people and travelers.

The invention relates to the technical field of medicines, in particular to application of an active ingredient xanthohumol (XAN) derived from a traditional Chinese medicine humulus lupulus in preparation of medicines for reducing uric acid and resisting gout, and the xanthohumol (XAN) can be prepared into various oral preparations, injection preparations and external preparations with the assistance of pharmaceutically acceptable auxiliary materials and has good development and application prospects. The inventor finds that the xanthohumol has relatively strong effects of reducing blood uric acid, resisting inflammation, resisting bone damage and the like, and the mechanism of the effect of reducing the blood uric acid is that the activity of xanthine oxidase is inhibited so as to reduce the generation of uric acid, and the renal function of an organism is improved so as to enhance uric acid excretion; according to the anti-inflammatory effect, the inflammatory reaction is relieved mainly by down-regulating the levels of inflammatory factors such as IL-1beta, IL-6, TNF alpha and PEG2; the mechanism for resisting gout bone damage is realized through the fact that RANKL / OPG / RANK signal pathway participates in bone metabolism regulation.

The invention relates to a long-acting oral medicine containing a hypoxia-inducible factor-proline hydroxylase inhibitor (HIF-PHI) and application of the long-acting oral medicine. Specifically, the present application discloses a long-acting oral pharmaceutical preparation containing a hypoxia-inducible factor-proline hydroxylase inhibitor (HIF-PHI) or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers, adjuvants or excipients, the long-acting oral pharmaceutical preparation being suitable for administration at an administration interval of one week or more, therefore, the composition is suitable for long-term administration in treatment of chronic anemia.

Pharmaceutical compositions are provided, which comprise cabozantinib or pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable excipient, wherein the inventive compositions exhibit enhanced bioavailability compared to the currently marketed or commercially available formulations. The present invention also provides manufacturing processes thereof and use of the said inventive compositions for the prevention, treatment or prophylaxis of disorders in human patients in need thereof. The present invention relates to oral pharmaceutical compositions of cabozantinib, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by cabozantinib.

The invention provides a preparation method of Al18F tracer integrated freeze-dried powder, a kit and application thereof, and the preparation method comprises the following steps: dissolving 1-10 mg of a precursor by using deionized water, adding a pH buffer solution with the concentration of 0.2-0.5 M and an AlCl3 solution with the concentration of 10 mM, with the ratio of the amount of substance of AlCl3 to the amount of substance of the precursor being 0.8-1.0, then continuously adding a stabilizer solution with the concentration of 0.5 M and 1-4 mg of an excipient, and uniformly stirring to obtain the Al18F tracer integrated freeze-dried powder. And finally, adding deionized water to enable the concentration of the precursor to be 0.5-1.0 mM, uniformly mixing the solution, sub-packaging the solution into 1.5 mL cryopreservation tubes or 2 mL penicillin bottles according to a certain volume, and then putting the cryopreservation tubes or the penicillin bottles into a vacuum freeze dryer to remove water at a low temperature to obtain powder or freeze-dried cakes, and the container is a freeze-dried powder / cake storage container and is used for storing the freeze-dried powder / cakes. Meanwhile, the reaction container is also used during radioactive labeling.

The invention discloses an anti-neurodegeneration exosome composition as well as a preparation method and application thereof. The anti-neurodegeneration exosome composition is prepared from the following components in parts by mass: 5 to 25 parts of human exfoliated deciduous tooth stem cell exosome, 25 to 85 parts of plant-derived exosome-like nano-vesicles, 12 to 10 parts of ginsenoside Rg, 2 to 10 parts of curcumin and 10 to 20 parts of auxiliary materials. The anti-neurodegeneration exosome composition contains a large amount of cell factors, growth factors, miRNA, mRNAs and other components, is easy to fuse with cell membranes of intestinal epithelial cells, can selectively deliver bioactive substances to recipient cells through a blood-brain barrier, carries out information transmission among different cells, regulates signal transduction among the cells, and has a good anti-neurodegeneration effect. The effects of resisting oxidation, resisting inflammation, resisting aging and the like are achieved.

The present invention provides compositions and methods for improving bone formation, bone mass, and / or strength, and / or treating or preventing bone loss, such as senescent bone loss, in a subject in need of such therapy. The composition comprises a homogeneous polysaccharide, or a pharmaceutically acceptable ester or salt thereof, or a pharmaceutically acceptable solvate thereof, or any combination thereof, and a pharmaceutically acceptable excipient. The homogeneous polysaccharide is mainly composed of arabinose, galactose, rhamnose and galacturonic acid as monomeric units. Such methods comprise administering to a subject in need thereof an effective dose of such a composition.

A solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD by lyophilizing a flash frozen stock solution of LSD and excipients, including a non-gelling matrix former, filler, and binder in a pre-formed mold, and forming an orally disintegrating tablet. A method of treating an individual by administering a solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet and treating the individual.

The present invention discloses an anti-aging composition, an anti-aging cosmetic and its preparation method and application. The anti-aging composition includes torreya grandis oil, hydrolyzed Brazil nut protein, angoloside C, carnosic acid and nanovesicle excipients. The present invention uses the above four natural plant components as anti-aging active ingredients, and from multiple perspectives such as promoting collagen synthesis, inhibiting the expression of inflammatory factors, scavenging free radicals, and repairing DNA damage, it exerts a significant anti-aging effect. The present invention encapsulates the above anti-aging active ingredients in the form of nanovesicles, which not only improves the stability of the active ingredients, but also improves the skin absorption effect of the active ingredients. The liposome nanovesicles have good compatibility with the matrix of the cosmetic, effectively solving the compatibility problem between the active ingredients and the cosmetic matrix.

A method of treating non-melanoma skin cancer in a patient in need thereof is provided. The method includes administering a hedgehog pathway inhibitor to the patient and applying to a region of skin on the patient, a topical composition comprising 5-aminolevulinic acid, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient. The method further includes incubating the topical composition on the region of skin; and illuminating the region of skin with a light source at an irradiance density of 20 mW / cm2.

Provided herein are pharmaceutical compositions, each comprising a phenylsulfonamide, for example, a compound of Formula I, or an enantiomer, a mixture of enantiomers, a mixture of tow ore more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; and a pharmaceutically acceptable excipient. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a neurodegenerative disease.

The invention belongs to the field of medicine, and relates to application of polydocanol in preparation of medicine for treating bromhidrosis through dispersion gridding subcutaneous multipoint continuous injection application, the polydocanol is a polydocanol injection, and each milliliter of the injection contains 5-30 mg of polydocanol. The invention further provides a medicine for treating bromhidrosis through dispersion gridding subcutaneous multipoint continuous injection application. The medicine comprises polydocanol and pharmaceutically acceptable auxiliary materials. The invention has the advantages of small trauma, simplicity and convenience in operation, high safety, longer treatment effect maintenance time and the like, and the long-term relieving effective rate is greater than 80%.